Characteristics of included studies
| First author, year published | Study design | Collaboration | Patients with SVR12 data | Mean age (years) | Male N (%) | Advanced fibrosis N (%) |
|---|---|---|---|---|---|---|
| Aqel, 201514 | Retrospective | Multicentre | 119 | 60 | 73 (61) | 119 (100) |
| Bichoupan, 201515 | Retrospective | Single centre | 97 | 60* | Not reported | 278 (54) |
| Capraru, 201416 | Prospective | Single centre | 34 | 57.7 | 31 (66) | Not reported |
| Czul, 201517 | Prospective | Single centre | 9 | Not reported | Not reported | 16 (89) |
| Dieterich, 201418 | Prospective | Multicentre | 276 | 59 | 181 (57) | 145 (45) |
| Kwo, 201519 | Prospective | Multicentre | 155 | 56* | 82 (53) | 0 (0) |
| Lawitz, 201410 | RCT | Multicentre | 82 | Not reported | 58 (81) | 41 (50) |
| Lawitz, 201520 | Prospective | Multicentre | 103 | 58* | 83 (81) | 103 (100) |
| Lin, 201421 | Retrospective | Multicentre | 121 | 57.7 | 103 (70) | 84 (57) |
| Lingala S et al, 201422 | Prospective | Single centre | 19 | 59 | 16 (64) | Not reported |
| Modi, 201423 | Prospective | Multicentre | 32 | 59* | 34 (76) | Not reported |
| Pearlman, 201524 | RCT | Single centre | 58 | 58 | 38 (66) | 58 (100) |
| Roytman, 201525 | Retrospective | Single centre | 52 | 61.5 | 63 (64) | 62 (63) |
| Saxena, 201526 | Retrospective | Multicentre | 156 | 62* | 95 (61) | 156 (100) |
| Singh, 201527 | Retrospective | Single centre | 76 | 62.8 | Not reported | 78 (100) |
*Median age presented.
RCT, randomised controlled trial; SVR12, sustained virological response at 12 weeks after end of treatment.